Cargando…
Improvement of cardiomyocyte function by in vivo hexarelin treatment in streptozotocin‐induced diabetic rats
Diabetic cardiomyopathy is characterized by diastolic and systolic cardiac dysfunction, yet no therapeutic drug to specifically treat it. Hexarelin has been demonstrated to improve heart function in various types of cardiomyopathy via its receptor GHS‐R. This experiment aims to test the effect of he...
Autores principales: | Zhang, Xinli, Qu, Linbing, Chen, Ling, Chen, Chen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5812882/ https://www.ncbi.nlm.nih.gov/pubmed/29446246 http://dx.doi.org/10.14814/phy2.13612 |
Ejemplares similares
-
Enhanced Pulsatile Growth Hormone Secretion and Altered Metabolic Hormones by in Vivo Hexarelin Treatment in Streptozotocin-Induced Diabetic Rats
por: Zhang, Xinli, et al.
Publicado: (2018) -
Hexarelin Protects Rodent Pancreatic Β-Cells Function from Cytotoxic Effects of Streptozotocin Involving Mitochondrial Signalling Pathways In Vivo and In Vitro
por: Zhao, Yan, et al.
Publicado: (2016) -
The cardiovascular action of hexarelin
por: Mao, Yuanjie, et al.
Publicado: (2014) -
Modulation of PTEN by hexarelin attenuates coronary artery ligation-induced heart failure in rats
por: AGBO, Elvis, et al.
Publicado: (2019) -
Hexarelin treatment preserves myocardial function and reduces cardiac fibrosis in a mouse model of acute myocardial infarction
por: McDonald, Hayley, et al.
Publicado: (2018)